Literature DB >> 16842376

Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.

Alan V Boddy1.   

Abstract

Advances in analytical methods, imaging techniques and an increased understanding of the influence of pharmacogenetic factors have added to our knowledge of the pharmacology of many chemotherapeutic agents. Extending the use of these approaches to pharmacodynamic end-points, together with the application of population-based modelling techniques, offers the potential to develop truly individualized therapy in the future.

Mesh：

Substances：

Year:  2006        PMID： 16842376      PMCID： PMC1885069          DOI： 10.1111/j.1365-2125.2006.02714.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  74 in total

1.  Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.

Authors:  Angela DeMichele; Richard Aplenc; Jeffrey Botbyl; Theresa Colligan; Lisa Wray; Melissa Klein-Cabral; Andrea Foulkes; Phyllis Gimotty; John Glick; Barbara Weber; Edward Stadtmauer; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.

Authors:  Gareth J Veal; Michael Cole; Julie Errington; Annie Parry; Juliet Hale; Andrew D J Pearson; Karen Howe; Julia C Chisholm; Carol Beane; Bernadette Brennan; Fiona Waters; Adam Glaser; Sue Hemsworth; Heather McDowell; Yvonne Wright; Kathy Pritchard-Jones; Ross Pinkerton; Gail Jenner; James Nicholson; Ann M Elsworth; Alan V Boddy
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

Review 3.  Pharmacokinetic/pharmacodynamic modelling in oncological drug development.

Authors:  Mats O Karlsson; Therese Anehall; Lena E Friberg; Anja Henningsson; Charlotte Kloft; Marie Sandström; Rujia Xie
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-03       Impact factor: 4.080

4.  An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.

Authors:  Joseph E Ippolito; Jian Xu; Sanjay Jain; Krista Moulder; Steven Mennerick; Jan R Crowley; R Reid Townsend; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

5.  Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.

Authors:  William P Petros; Penelope J Hopkins; Susan Spruill; Gloria Broadwater; James J Vredenburgh; O Michael Colvin; William P Peters; Roy B Jones; Jeff Hall; Jeffrey R Marks
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

6.  A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells.

Authors:  Takahiro Yamauchi; Takanori Ueda
Journal:  Biochem Pharmacol       Date:  2005-04-26       Impact factor: 5.858

7.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.

Authors:  Anders Jakobsen; Jens Nederby Nielsen; Niels Gyldenkerne; Jan Lindeberg
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

8.  Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.

Authors:  Wolfram E Samlowski; Sancy A Leachman; Mark Wade; Pamela Cassidy; Patricia Porter-Gill; Leslie Busby; Richard Wheeler; Kenneth Boucher; Frank Fitzpatrick; David A Jones; Adam R Karpf
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

9.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 10.  Identifying DNA methylation biomarkers of cancer drug response.

Authors:  Sabine Maier; Christina Dahlstroem; Carolina Haefliger; Achim Plum; Christian Piepenbrock
Journal:  Am J Pharmacogenomics       Date:  2005
View more
  1 in total

1.  Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.

Authors:  L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.